Max Healthcare revises oncology expectations as project timelines slip
Management admits oncology revenue share will remain below historical peaks while deferring completion dates for major hospital projects in Gurgaon and Lucknow.
What's new
- Oncology revenue mix dropped to 21% from 26% year-on-year.
- Board approved ₹1,400 cr for a 700-bed greenfield hospital in Lucknow.
- Lucknow brownfield capacity expansion deferred by two quarters.
Key quotes
-
"We don't expect the share of oncology to come back to 25-26% as it was earlier. It will continue to hover around 21-22%."
— Abhay Soi, Chairman -
"The board has approved an investment of 1,400 crores for the construction of a 700-bed greenfield hospital at Shaheed Path, Lucknow."
— Abhay Soi, Chairman
The brief
Max Healthcare is recalibrating its growth model as oncology face-plants under CGHS pricing mandates. Management’s admission that oncology's contribution won't return to 25-26% marks a permanent shift in the hospital’s revenue profile. This is complicated by persistent project delays. Gurgaon’s 500-bed facility has slipped from a H1 FY27 target to year-end, while Lucknow’s capacity expansion missed prior guidance markers, now deferred two more quarters to reach 570 beds. The new ₹1,400 cr investment for a 700-bed greenfield site in Lucknow signals long-term intent, but the operational reality involves missed timelines and margin-dilutive specialty shifts. Recurring guidance revisions are difficult to reconcile with a premium valuation. The Lucknow growth plan is ambitious, yet the immediate path remains more elastic than management’s earlier projections. The company needs to hit its next set of dates to prove the strategy is grounded in reality.
Max Healthcare is trading oncology-led margins for volume-heavy greenfield bets, but its recurring habit of missing project timelines remains a credibility risk.